Cellebrite DI Ltd. (NASDAQ:CLBT) Given Average Recommendation of “Moderate Buy” by Brokerages

Cellebrite DI Ltd. (NASDAQ:CLBT) has received a consensus recommendation of “Moderate Buy” from the five ratings firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $24.00.

Several brokerages have commented on CLBT. Bank of America lifted their price objective on shares of Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. JPMorgan Chase & Co. increased their price objective on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. Wall Street Zen downgraded shares of Cellebrite DI from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Lake Street Capital upped their price target on shares of Cellebrite DI from $22.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Finally, Needham & Company LLC increased their price target on Cellebrite DI from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th.

Cellebrite DI Stock Performance

Cellebrite DI stock opened at $17.00 on Friday. The business’s 50-day simple moving average is $17.93 and its two-hundred day simple moving average is $16.93. The company has a market cap of $4.07 billion, a PE ratio of 54.84, a PEG ratio of 2.43 and a beta of 1.28. Cellebrite DI has a fifty-two week low of $13.10 and a fifty-two week high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last released its earnings results on Wednesday, November 12th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.05). The firm had revenue of $126.03 million for the quarter, compared to analyst estimates of $122.98 million. Cellebrite DI had a return on equity of 20.81% and a net margin of 16.74%.The company’s revenue for the quarter was up 17.9% compared to the same quarter last year. During the same period last year, the firm earned $0.14 EPS. As a group, analysts predict that Cellebrite DI will post 0.3 EPS for the current fiscal year.

Institutional Trading of Cellebrite DI

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Y.D. More Investments Ltd grew its stake in shares of Cellebrite DI by 76.2% during the 2nd quarter. Y.D. More Investments Ltd now owns 441,579 shares of the company’s stock worth $7,065,000 after purchasing an additional 191,020 shares during the period. Y Intercept Hong Kong Ltd purchased a new stake in Cellebrite DI during the second quarter worth $657,000. Moody National Bank Trust Division purchased a new stake in Cellebrite DI during the third quarter worth $2,670,000. MQS Management LLC acquired a new stake in Cellebrite DI during the second quarter valued at $256,000. Finally, Venturi Wealth Management LLC purchased a new position in Cellebrite DI in the second quarter valued at $224,000. 45.88% of the stock is owned by institutional investors and hedge funds.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.